160 related articles for article (PubMed ID: 27021747)
1. Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia.
Tilden D; Guarnieri C
Value Health; 2016; 19(2):145-52. PubMed ID: 27021747
[TBL] [Abstract][Full Text] [Related]
2. [Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].
Sanz-Granda A; Marti MJ; Catalan MJ
Rev Neurol; 2018 Dec; 67(12):465-472. PubMed ID: 30536360
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial.
Wickwar S; McBain H; Newman SP; Hirani SP; Hurt C; Dunlop N; Flood C; Ezra DG
Trials; 2016 Mar; 17(1):129. PubMed ID: 26961367
[TBL] [Abstract][Full Text] [Related]
4. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
Hamid R; Loveman C; Millen J; Globe D; Corbell C; Colayco D; Stanisic S; Gultyaev D
Pharmacoeconomics; 2015 Apr; 33(4):381-93. PubMed ID: 25526842
[TBL] [Abstract][Full Text] [Related]
7. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
8. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
9. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
10. A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
Med Lett Drugs Ther; 2010 Nov; 52(1351):90-1. PubMed ID: 21068703
[TBL] [Abstract][Full Text] [Related]
11. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.
Trosch RM; Shillington AC; English ML; Marchese D
J Manag Care Spec Pharm; 2015 Oct; 21(10):854-60. PubMed ID: 26402386
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
[TBL] [Abstract][Full Text] [Related]
14. Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias.
De Bartolo MI; Manzo N; Ferrazzano G; Baione V; Belvisi D; Fabbrini G; Berardelli A; Conte A
Toxins (Basel); 2020 Apr; 12(5):. PubMed ID: 32344856
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
Danchenko N; Johnston KM; Whalen J
J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
[TBL] [Abstract][Full Text] [Related]
16. Multidose Botulinum Toxin A for Intralaryngeal Injection: A Cost Analysis.
Gilbert MR; Young VN; Smith LJ; Rosen CA
J Voice; 2019 Mar; 33(2):159-161. PubMed ID: 29307768
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective.
Makino K; Tilden D; Guarnieri C; Mudge M; Baguley IJ
Pharmacoecon Open; 2019 Mar; 3(1):93-102. PubMed ID: 29915932
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
Ademi Z; Pasupathi K; Liew D
Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
[TBL] [Abstract][Full Text] [Related]
20. [Long-term treatment with botulinum toxin: dosage, treatment schedules and costs].
Schnider P; Birner P; Moraru E; Auff E
Wien Klin Wochenschr; 1999 Jan; 111(2):59-65. PubMed ID: 10081123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
